Tenaya Therapeutics, Inc. — Form 8-K Summary
Reporting period/event date: June 8, 2023; filed June 12, 2023. The filing reports actions taken at the 2023 Annual Meeting of Stockholders and amendments approved by the board and stockholders.
Business Context and Financial Metrics
The filing concerns corporate governance, executive severance arrangements, and annual meeting results. It does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial performance metrics.
Material Changes and Corporate Actions
- Executive severance plan: The board amended the Executive Change in Control and Severance Plan and approved amended and restated participation agreements for current participants and a new form for future participants.
- Severance outside a change in control: Named executive officers generally receive nine months of base salary and nine months of COBRA coverage or equivalent payment. CEO Faraz Ali is eligible for 12 months of each.
- Severance following a change in control: Eligible executives generally receive 12 months of base salary, 100% of target annual bonus, 12 months of COBRA coverage or equivalent payment, and full accelerated vesting of outstanding equity awards, including performance awards at 100% of target. Mr. Ali is eligible for 18 months of salary and health coverage and 150% of target bonus.
- Certificate of incorporation: The company filed an effective amendment adopting Delaware-law provisions limiting monetary liability of directors and officers for breaches of fiduciary duty to the fullest extent permitted by law.
- Director elections: Amy Burroughs, Jin-Long Chen, and Catherine Stehman-Breen were elected as Class II directors, each serving until the 2026 annual meeting or until a successor is qualified.
- Auditor ratification: Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Voting Results
| Proposal | For | Against | Abstain | Broker non-votes |
|---|---|---|---|---|
| Amy Burroughs election | 56,813,999 | 120,571 withheld | Not separately reported | 3,354,787 |
| Jin-Long Chen election | 54,315,499 | 2,619,071 withheld | Not separately reported | 3,354,787 |
| Catherine Stehman-Breen election | 56,678,838 | 255,732 withheld | Not separately reported | 3,354,787 |
| Auditor ratification | 60,277,871 | 11,275 | 211 | 0 |
| Officer exculpation amendment | 55,753,278 | 1,173,172 | 8,120 | 3,354,787 |
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The principal potential financial exposure disclosed is the increased severance, bonus, health-benefit, and equity-vesting obligations upon qualifying executive terminations, particularly following a change in control. The officer-exculpation amendment may limit monetary liability to the extent permitted by Delaware law but does not eliminate liability where such protection is unavailable.
Investor Verification Items
- Review Exhibit 10.1 for the complete definitions of qualifying termination, cause, good reason, disability, and change in control.
- Assess the potential dilution and expense implications of full accelerated vesting of outstanding equity awards.
- Confirm executive participation agreements and the number and value of awards subject to the amended plan.
- Review Exhibit 3.1 and applicable Delaware law to determine the scope and limitations of officer exculpation.
- Refer to the company’s periodic financial filings for current cash, liquidity, operating results, and funding needs, which are not provided in this Form 8-K.